Yang-Yan Yi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yang-Yan Yi has a total of 80 co-authors. Here are the top co-authors by number of shared publications:
Shu Wu
Department of Plastic Surgery, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, People’s Republic of China
13 shared publicationsYuan-Zheng Zhu
Department of Plastic Surgery, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, People’s Republic of China
12 shared publicationsYuanzheng Zhu
7 shared publicationsXuan Hu
From the Department of Plastic Surgery, The Second Affiliated Hospital of Nanchang University, Jiangxi, People's Republic of China
6 shared publicationsZhao-Hui Wang
Department of Plastic Surgery, The Second Affiliated Hospital of Nanchang Universityand
5 shared publicationsJing Zhang
From the Department of Plastic Surgery, The Second Affiliated Hospital of Nanchang University, Jiangxi, P.R. China
4 shared publications
Latest Publications
- Open Access
- 25 February 2026
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 24 (1)
Nanotherapeutic strategy via ADSC-mitoEVs rescues ischaemic angiogenesis through mitophagy and mitochondrial metabolic reprogramming
Ischaemic vascular diseases are critically linked to mitochondrial dysfunction in endothelial cells, which impairs angiogenesis and tissue repair. Although
- 25 February 2026
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 24 (1)
Open AccessNanotherapeutic strategy via ADSC-mitoEVs rescues ischaemic angiogenesis through mitophagy and mitochondrial metabolic reprogramming
Ischaemic vascular diseases are critically linked to mitochondrial dysfunction in endothelial cells, which impairs angiogenesis and tissue repair. Although
- Open Access
- 14 February 2026
- Published by Elsevier in SSRN Electronic Journal
Root-System-Inspired Core–Shell Microneedles Enable Spatiotemporal Sequential Therapy via ROS Scavenging, Angiogenesis, and Capillary-Driven Lipid Removal for Enhanced Fat Graft Survival
The high resorption rate (40–60%) in fat grafting stems from a vicious inflammatory cycle driven by initial ischemia–hypoxia and subsequent lipid spillover. To simultaneously intervene in these two critical phases, we developed a spatiotemporally regulated core–shell microneedle system. The shell is composed of a ROS-responsive silk-fibroin-based hydrogel that scavenges reactive oxygen species and releases vascular endothelial growth factor to promote early-stage vascularization. The core consists of lipophilic poly(lactic-co-glycolic acid) engineered with micro-grooves and a porous tip, enabling active adsorption and removal of necrotic lipid droplets, thereby directly eliminating the source of chronic inflammation. In a murine model, this system significantly improved graft survival, reduced inflammation and fibrosis, and maintained adipocyte viability. Transcriptomic analysis further revealed its ability to upregulate pathways related to angiogenesis and lipid metabolism while suppressing key inflammatory signaling networks such as NF-κB. This “promote-vessel-first, remove-lipid-second” sequential strategy offers an integrated therapeutic solution for fat grafting and establishes a new paradigm for intervening in lipotoxicity-driven diseases through physical clearance.
- 14 February 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessRoot-System-Inspired Core–Shell Microneedles Enable Spatiotemporal Sequential Therapy via ROS Scavenging, Angiogenesis, and Capillary-Driven Lipid Removal for Enhanced Fat Graft Survival
The high resorption rate (40–60%) in fat grafting stems from a vicious inflammatory cycle driven by initial ischemia–hypoxia and subsequent lipid spillover. To simultaneously intervene in these two critical phases, we developed a spatiotemporally regulated core–shell microneedle system. The shell is composed of a ROS-responsive silk-fibroin-based hydrogel that scavenges reactive oxygen species and releases vascular endothelial growth factor to promote early-stage vascularization. The core consists of lipophilic poly(lactic-co-glycolic acid) engineered with micro-grooves and a porous tip, enabling active adsorption and removal of necrotic lipid droplets, thereby directly eliminating the source of chronic inflammation. In a murine model, this system significantly improved graft survival, reduced inflammation and fibrosis, and maintained adipocyte viability. Transcriptomic analysis further revealed its ability to upregulate pathways related to angiogenesis and lipid metabolism while suppressing key inflammatory signaling networks such as NF-κB. This “promote-vessel-first, remove-lipid-second” sequential strategy offers an integrated therapeutic solution for fat grafting and establishes a new paradigm for intervening in lipotoxicity-driven diseases through physical clearance.
- Open Access
- 22 January 2026
- Published by Oxford University Press (OUP) in Regenerative Biomaterials
- Vol. 13
A ‘frost formation’-inspired near-infrared-responsive nitric oxide-releasing hydrogel for enhancing fat graft survival
Soft tissue defects represent a major challenge in plastic surgery, for which autologous fat grafting remains the standard treatment. However, in the early post-transplant period, the grafted fat tissue undergoes ischemia and hypoxia, leading to low and markedly unpredictable survival rates that consequently compromise the aesthetic outcomes. Nitric oxide (NO), an endogenous gasotransmitter, plays a vital role in mediating angiogenesis and vascular remodeling. Therefore, we developed a near-infrared-responsive hydrogel that releases NO on demand to promote adipocyte vascularization and thereby improve graft retention and enable precise volumetric filling. To ensure high filling, the platform incorporates a photosensitive gelatin methacryloyl (GelMA) hydrogel inspired by the rapid solidification of ‘frost formation’. The hydrogel can be precisely delivered to the target area and photocrosslinked in situ to form a three-dimensional network that supports cell growth. Notably, this photocrosslinking process does not require ultraviolet irradiation, thereby eliminating the associated risks and significantly greatly enhancing the safety of adipose remodeling and filling technologies. Experimental studies conducted both in vitro and in vivo have validated that this hydrogel platform ensures precise grafting, promotes graft integration and significantly improves the long-term survival of transplanted adipose tissue.
- 22 January 2026
- Published by Oxford University Press (OUP) in Regenerative Biomaterials
- Vol. 13
Open AccessA ‘frost formation’-inspired near-infrared-responsive nitric oxide-releasing hydrogel for enhancing fat graft survival
Soft tissue defects represent a major challenge in plastic surgery, for which autologous fat grafting remains the standard treatment. However, in the early post-transplant period, the grafted fat tissue undergoes ischemia and hypoxia, leading to low and markedly unpredictable survival rates that consequently compromise the aesthetic outcomes. Nitric oxide (NO), an endogenous gasotransmitter, plays a vital role in mediating angiogenesis and vascular remodeling. Therefore, we developed a near-infrared-responsive hydrogel that releases NO on demand to promote adipocyte vascularization and thereby improve graft retention and enable precise volumetric filling. To ensure high filling, the platform incorporates a photosensitive gelatin methacryloyl (GelMA) hydrogel inspired by the rapid solidification of ‘frost formation’. The hydrogel can be precisely delivered to the target area and photocrosslinked in situ to form a three-dimensional network that supports cell growth. Notably, this photocrosslinking process does not require ultraviolet irradiation, thereby eliminating the associated risks and significantly greatly enhancing the safety of adipose remodeling and filling technologies. Experimental studies conducted both in vitro and in vivo have validated that this hydrogel platform ensures precise grafting, promotes graft integration and significantly improves the long-term survival of transplanted adipose tissue.
- 8 January 2026
- Published by Springer Nature in Aesthetic Plastic Surgery
- Vol. 50 (11) , 4203-4211
Temporal Transcriptomic Mapping Reveals Angiogenesis and Immune Remodeling During Fat Grafting
Background Autologous fat grafting is limited by unpredictable resorption and complications, largely due to inadequate revascularization and persistent inflammation. The molecular mechanisms underlying these processes remain poorly understood. Methods Human fat grafts were implanted into nude mice and harvested at days 3, 7, 14, 21, and 28 for RNA sequencing. Differentially expressed genes (DEGs) were identified and functionally annotated using GO and KEGG analyses. Key candidates were validated via RT-PCR. Results Human-derived RNA decreased sharply after day 3, indicating graft cell death. Grafts at day 3 showed upregulation of hypoxia-response pathways (HIF-1, glycolysis) and downregulation of oxidative metabolism and adipogenesis. Recipient-derived transcriptomes revealed sustained upregulation of angiogenesis and ECM-related genes (Fgf1, Plau, and Ccbe1) and downregulation of inflammatory genes (Ccr2 and Relt). Dynamic changes were most pronounced between days 3 and 14, followed by stabilization. Conclusion Early fat grafting is characterized by metabolic adaptation to hypoxia and active host-mediated angiogenesis and inflammation resolution. Key genes identified may serve as therapeutic targets to enhance graft survival. This study provides a temporal transcriptomic atlas that elucidates the molecular basis of graft integration. No Level Assigned This journal requires that authors assign a level of evidence to each submission to which Evidence-Based Medicine rankings are applicable. This excludes Review Articles, Book Reviews, and manuscripts that concern Basic Science, Animal Studies, Cadaver Studies, and Experimental Studies. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266
- 8 January 2026
- Published by Springer Nature in Aesthetic Plastic Surgery
- Vol. 50 (11) , 4203-4211
Temporal Transcriptomic Mapping Reveals Angiogenesis and Immune Remodeling During Fat Grafting
Background Autologous fat grafting is limited by unpredictable resorption and complications, largely due to inadequate revascularization and persistent inflammation. The molecular mechanisms underlying these processes remain poorly understood. Methods Human fat grafts were implanted into nude mice and harvested at days 3, 7, 14, 21, and 28 for RNA sequencing. Differentially expressed genes (DEGs) were identified and functionally annotated using GO and KEGG analyses. Key candidates were validated via RT-PCR. Results Human-derived RNA decreased sharply after day 3, indicating graft cell death. Grafts at day 3 showed upregulation of hypoxia-response pathways (HIF-1, glycolysis) and downregulation of oxidative metabolism and adipogenesis. Recipient-derived transcriptomes revealed sustained upregulation of angiogenesis and ECM-related genes (Fgf1, Plau, and Ccbe1) and downregulation of inflammatory genes (Ccr2 and Relt). Dynamic changes were most pronounced between days 3 and 14, followed by stabilization. Conclusion Early fat grafting is characterized by metabolic adaptation to hypoxia and active host-mediated angiogenesis and inflammation resolution. Key genes identified may serve as therapeutic targets to enhance graft survival. This study provides a temporal transcriptomic atlas that elucidates the molecular basis of graft integration. No Level Assigned This journal requires that authors assign a level of evidence to each submission to which Evidence-Based Medicine rankings are applicable. This excludes Review Articles, Book Reviews, and manuscripts that concern Basic Science, Animal Studies, Cadaver Studies, and Experimental Studies. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266
- Open Access
- 6 January 2026
- Published by Oxford University Press (OUP) in Burns & Trauma
- Vol. 14
Root-system-inspired core–shell microneedles enable spatiotemporal sequential therapy via ROS scavenging, angiogenesis, and capillary-driven lipid removal for enhanced fat graft survival
Background: Autologous fat grafting is widely used in reconstructive and esthetic surgery, but its clinical outcomes are limited by early ischemia–hypoxia, oxidative stress, delayed vascularization, and subsequent lipid accumulation-induced inflammation. Current therapeutic strategies generally focus on single-stage regulation and lack temporal coordination with the dynamic pathological evolution of transplanted adipose tissue. Here, we developed a root system-inspired core–shell microneedle (MN) platform capable of sequentially regulating the graft microenvironment through early vascular promotion and later lipid removal. Methods: Vascular endothelial growth factor-loaded modified silk fibroin methacryloyl/grooved poly(lactic-co-glycolic acid) core–shell MNs (VEGF@mSF/gPLGA–MNs) were fabricated by integrating a reactive oxygen species (ROS)-responsive mSF shell with a lipid-adsorbing gPLGA core. The physicochemical properties, ROS scavenging ability, VEGF release behavior, and lipid adsorption capacity of the MNs were systematically characterized. Their biological effects were evaluated using in vitro cellular assays and a mouse autologous fat grafting model. Graft survival, vascularization, inflammatory regulation, and adipose remodeling and the underlying molecular mechanisms were assessed by imaging, histological analyses, immunofluorescence staining, ribonucleic acid sequencing, and western blotting. Results: The mSF shell rapidly responded to oxidative stress and degraded during the early stage after implantation, enabling localized VEGF release while alleviating ROS-induced cellular damage. Following shell degradation, the exposed gPLGA core facilitated directional lipid adsorption owing to its lipophilic properties and groove-mediated capillary transport. In vitro studies demonstrated improved endothelial migration, angiogenesis, ROS clearance, and mitochondrial protection. In a mouse fat graft model, VEGF@mSF/gPLGA–MNs significantly improved graft retention, reduced cystic degeneration and fibrosis, increased vascularization, and promoted adipose tissue remodeling. Transcriptomic and protein analyses revealed that lipid metabolism-related pathways, including PPAR signaling, were activated, and that inflammatory pathways, such as the NF-κB, TNF, IL-17, and toll-like receptor signaling pathways, were suppressed. Conclusions: The root system-inspired VEGF@mSF/gPLGA–MN platform enables spatiotemporally sequential regulation of the fat graft microenvironment by coordinating early vascular reconstruction with subsequent lipid clearance. This strategy provides a promising approach for improving fat graft survival and may offer a generalizable paradigm for regenerative therapies involving dynamic pathological transitions.
- 6 January 2026
- Published by Oxford University Press (OUP) in Burns & Trauma
- Vol. 14
Open AccessRoot-system-inspired core–shell microneedles enable spatiotemporal sequential therapy via ROS scavenging, angiogenesis, and capillary-driven lipid removal for enhanced fat graft survival
Background: Autologous fat grafting is widely used in reconstructive and esthetic surgery, but its clinical outcomes are limited by early ischemia–hypoxia, oxidative stress, delayed vascularization, and subsequent lipid accumulation-induced inflammation. Current therapeutic strategies generally focus on single-stage regulation and lack temporal coordination with the dynamic pathological evolution of transplanted adipose tissue. Here, we developed a root system-inspired core–shell microneedle (MN) platform capable of sequentially regulating the graft microenvironment through early vascular promotion and later lipid removal. Methods: Vascular endothelial growth factor-loaded modified silk fibroin methacryloyl/grooved poly(lactic-co-glycolic acid) core–shell MNs (VEGF@mSF/gPLGA–MNs) were fabricated by integrating a reactive oxygen species (ROS)-responsive mSF shell with a lipid-adsorbing gPLGA core. The physicochemical properties, ROS scavenging ability, VEGF release behavior, and lipid adsorption capacity of the MNs were systematically characterized. Their biological effects were evaluated using in vitro cellular assays and a mouse autologous fat grafting model. Graft survival, vascularization, inflammatory regulation, and adipose remodeling and the underlying molecular mechanisms were assessed by imaging, histological analyses, immunofluorescence staining, ribonucleic acid sequencing, and western blotting. Results: The mSF shell rapidly responded to oxidative stress and degraded during the early stage after implantation, enabling localized VEGF release while alleviating ROS-induced cellular damage. Following shell degradation, the exposed gPLGA core facilitated directional lipid adsorption owing to its lipophilic properties and groove-mediated capillary transport. In vitro studies demonstrated improved endothelial migration, angiogenesis, ROS clearance, and mitochondrial protection. In a mouse fat graft model, VEGF@mSF/gPLGA–MNs significantly improved graft retention, reduced cystic degeneration and fibrosis, increased vascularization, and promoted adipose tissue remodeling. Transcriptomic and protein analyses revealed that lipid metabolism-related pathways, including PPAR signaling, were activated, and that inflammatory pathways, such as the NF-κB, TNF, IL-17, and toll-like receptor signaling pathways, were suppressed. Conclusions: The root system-inspired VEGF@mSF/gPLGA–MN platform enables spatiotemporally sequential regulation of the fat graft microenvironment by coordinating early vascular reconstruction with subsequent lipid clearance. This strategy provides a promising approach for improving fat graft survival and may offer a generalizable paradigm for regenerative therapies involving dynamic pathological transitions.
- Open Access
- 22 November 2025
- Published by Elsevier in Photodiagnosis and Photodynamic Therapy
- Vol. 56, 105295
A Bibliometric Analysis of the Global Research Landscape and Trends in Photoaging Therapy (2015–2024)
- 22 November 2025
- Published by Elsevier in Photodiagnosis and Photodynamic Therapy
- Vol. 56, 105295
Open AccessA Bibliometric Analysis of the Global Research Landscape and Trends in Photoaging Therapy (2015–2024)
- Open Access
- 31 October 2025
- Published by Springer Nature in Research Square
Nanotherapeutic Strategy via ADSC-mitoEVs Rescues Ischemic Angiogenesis through Mitophagy and Mitochondrial Metabolic Reprogramming
Ischemic vascular diseases are critically associated with mitochondrial dysfunction in endothelial cells, leading to impaired angiogenesis and compromised tissue repair. Although mitochondrial transfer has emerged as a promising therapeutic strategy for revascularization, its clinical translation has been hindered by inefficient delivery systems. In this study, we show that mitochondrial-enriched extracellular vesicles derived from adipose-derived stem cells (ADSC-mitoEVs) function as an efficient nanotherapeutic, restoring angiogenic function both in vitro and in a murine model of diabetic hindlimb ischemia. Mechanistically, the uptake of ADSC-mitoEVs triggered PINK1/Parkin-mediated mitophagy in recipient endothelial cells, a process essential for initiating angiogenesis. Moreover, ADSC-mitoEVs directly delivered functional mitochondrial proteins, including superoxide dismutase 2 (SOD2), into the endogenous mitochondrial network, which enhanced antioxidant defense and improved bioenergetic capacity independently of mitophagy, as shown by reduced reactive oxygen species and elevated ATP production even in PINK1-silenced cells. Our results demonstrate ADSC-mitoEVs as a versatile, cell-free nanotherapeutic that promotes mitochondrial quality control and metabolic reprogramming, offering a potent therapeutic avenue for ischemic vascular diseases.
- 31 October 2025
- Published by Springer Nature in Research Square
Open AccessNanotherapeutic Strategy via ADSC-mitoEVs Rescues Ischemic Angiogenesis through Mitophagy and Mitochondrial Metabolic Reprogramming
Ischemic vascular diseases are critically associated with mitochondrial dysfunction in endothelial cells, leading to impaired angiogenesis and compromised tissue repair. Although mitochondrial transfer has emerged as a promising therapeutic strategy for revascularization, its clinical translation has been hindered by inefficient delivery systems. In this study, we show that mitochondrial-enriched extracellular vesicles derived from adipose-derived stem cells (ADSC-mitoEVs) function as an efficient nanotherapeutic, restoring angiogenic function both in vitro and in a murine model of diabetic hindlimb ischemia. Mechanistically, the uptake of ADSC-mitoEVs triggered PINK1/Parkin-mediated mitophagy in recipient endothelial cells, a process essential for initiating angiogenesis. Moreover, ADSC-mitoEVs directly delivered functional mitochondrial proteins, including superoxide dismutase 2 (SOD2), into the endogenous mitochondrial network, which enhanced antioxidant defense and improved bioenergetic capacity independently of mitophagy, as shown by reduced reactive oxygen species and elevated ATP production even in PINK1-silenced cells. Our results demonstrate ADSC-mitoEVs as a versatile, cell-free nanotherapeutic that promotes mitochondrial quality control and metabolic reprogramming, offering a potent therapeutic avenue for ischemic vascular diseases.
- 2 October 2025
- Published by Wiley in The FASEB Journal
- Vol. 39 (19) , e70969
Creatine Supplementation Enhances Fat Graft Survival by Mitochondrial Protection and Revascularization Promotion
Autologous fat grafting is compromised by post‐grafting ischemic necrosis and volumetric resorption, clinical challenges stemming from inadequate vascularization and metabolic stress. Here, we identify oral creatine supplementation as a translatable metabolic therapy to enhance fat graft survival. Through adipose organoids and a murine grafting model, we demonstrate that creatine stabilizes mitochondrial membrane potential (ΔΨm), reduces reactive oxygen species (ROS), and redirects energy production toward non‐mitochondrial ATP synthesis, collectively promoting adipocyte survival and revascularization. Mechanistically, creatine activates a phosphocreatine‐kinase shuttle to sustain ATP pools independently of oxidative phosphorylation, while concurrently mitigating electron transport chain‐derived oxidative damage. The therapeutic equivalence of systemic and localized delivery routes, combined with creatine's FDA‐approved safety profile, positions this intervention as a clinically viable strategy to improve fat grafting outcomes.
- 2 October 2025
- Published by Wiley in The FASEB Journal
- Vol. 39 (19) , e70969
Creatine Supplementation Enhances Fat Graft Survival by Mitochondrial Protection and Revascularization Promotion
Autologous fat grafting is compromised by post‐grafting ischemic necrosis and volumetric resorption, clinical challenges stemming from inadequate vascularization and metabolic stress. Here, we identify oral creatine supplementation as a translatable metabolic therapy to enhance fat graft survival. Through adipose organoids and a murine grafting model, we demonstrate that creatine stabilizes mitochondrial membrane potential (ΔΨm), reduces reactive oxygen species (ROS), and redirects energy production toward non‐mitochondrial ATP synthesis, collectively promoting adipocyte survival and revascularization. Mechanistically, creatine activates a phosphocreatine‐kinase shuttle to sustain ATP pools independently of oxidative phosphorylation, while concurrently mitigating electron transport chain‐derived oxidative damage. The therapeutic equivalence of systemic and localized delivery routes, combined with creatine's FDA‐approved safety profile, positions this intervention as a clinically viable strategy to improve fat grafting outcomes.
- 22 May 2025
- Published by SAGE Publications in The International Journal of Lower Extremity Wounds
- Vol. 25 (4) , 1248-1256
Chronic Kidney Disease as an Independent Risk Factor for Chronic Lower Extremity Ulcers: A Cross-Sectional Analysis of US Adults
Background: Chronic lower extremity ulcers (CLEU) are a significant health burden, often linked to complications such as diabetes and vascular diseases. Chronic kidney disease (CKD), a prevalent global health issue, has been increasingly associated with CLEU, though the nature of this relationship remains poorly understood. This study aimed to explore the association between CKD and CLEU in the US adult population. Methods: We analyzed data from the National Health and Nutrition Examination Survey (NHANES) between 1999 and 2004. The study included adults aged 20 years and older who completed interviews and examinations. CLEU was defined as self-reported ulcers or sores on the leg or foot lasting more than four weeks. CKD was diagnosed based on the 2012 KDIGO guidelines, using estimated glomerular filtration rate (eGFR) and urinary albumin-to-creatinine ratio (UACR). Logistic regression models were used to assess the association between CKD and CLEU, adjusting for demographics, BMI, lifestyle factors, and comorbidities. Results: Among 8564 participants, individuals with CKD had a higher likelihood of developing CLEU, with an unadjusted odds ratio (OR) of 2.33 (95% CI: 1.86-2.91). After adjusting for confounders, the association remained significant, with adjusted ORs of 1.64 (95% CI: 1.26-2.12) and 1.57 (95% CI: 1.2-2.04) in Models 2 and 3, respectively. Stratified analyses showed no significant interactions across subgroups defined by age, sex, diabetes, hypertension, hyperlipidemia, and peripheral artery disease (PAD). Conclusion: This study demonstrates a robust association between CKD and CLEU in US adults, suggesting that CKD is an independent risk factor for CLEU. These findings highlight the need for integrated management strategies for CKD patients to reduce the risk of CLEU. Future longitudinal studies are needed to establish causality and inform targeted interventions.
- 22 May 2025
- Published by SAGE Publications in The International Journal of Lower Extremity Wounds
- Vol. 25 (4) , 1248-1256
Chronic Kidney Disease as an Independent Risk Factor for Chronic Lower Extremity Ulcers: A Cross-Sectional Analysis of US Adults
Background: Chronic lower extremity ulcers (CLEU) are a significant health burden, often linked to complications such as diabetes and vascular diseases. Chronic kidney disease (CKD), a prevalent global health issue, has been increasingly associated with CLEU, though the nature of this relationship remains poorly understood. This study aimed to explore the association between CKD and CLEU in the US adult population. Methods: We analyzed data from the National Health and Nutrition Examination Survey (NHANES) between 1999 and 2004. The study included adults aged 20 years and older who completed interviews and examinations. CLEU was defined as self-reported ulcers or sores on the leg or foot lasting more than four weeks. CKD was diagnosed based on the 2012 KDIGO guidelines, using estimated glomerular filtration rate (eGFR) and urinary albumin-to-creatinine ratio (UACR). Logistic regression models were used to assess the association between CKD and CLEU, adjusting for demographics, BMI, lifestyle factors, and comorbidities. Results: Among 8564 participants, individuals with CKD had a higher likelihood of developing CLEU, with an unadjusted odds ratio (OR) of 2.33 (95% CI: 1.86-2.91). After adjusting for confounders, the association remained significant, with adjusted ORs of 1.64 (95% CI: 1.26-2.12) and 1.57 (95% CI: 1.2-2.04) in Models 2 and 3, respectively. Stratified analyses showed no significant interactions across subgroups defined by age, sex, diabetes, hypertension, hyperlipidemia, and peripheral artery disease (PAD). Conclusion: This study demonstrates a robust association between CKD and CLEU in US adults, suggesting that CKD is an independent risk factor for CLEU. These findings highlight the need for integrated management strategies for CKD patients to reduce the risk of CLEU. Future longitudinal studies are needed to establish causality and inform targeted interventions.
- 25 April 2025
- Published by Springer Nature in Aesthetic Plastic Surgery
- p. 1-11
Postoperative Intermittent Fasting Improves Outcome of Autologous Fat Grafting in Mice
Background Autologous fat grafting confronts challenges of inconsistent retention and complications. Intermittent fasting (IF), an emerging dietary management strategy, shows potential in tissue repair and fat metabolism, and yet to know in fat grafting. Objectives The aim of this study is to address the impact of 16:8 IF on the outcome of fat grafting in mice. Methods Male C57BL/6 mice were randomly assigned to postoperative IF regimen group (n = 24) and ad libitum group with unrestricted feeding (n = 24). For postoperative IF group, animals were put on a feeding schedule with 8 hours of unrestricted access to standard diet per day followed by 16-h fasting period after fat grafting. Fat grafts were harvested at 2, 4 and 12 weeks postoperatively. We addressed the mass retention and graft quality through weighting and ultrasound examination. Histological remodeling of fat grafts was evaluated by Masson staining and immunofluorescence staining. Results In comparison with unrestricted feeding, postoperative IF strategies improved the mass retention of fat grafts, and optimized the outcomes characterized by enhanced adipogenesis, accelerated revascularization, facilitated M2 macrophage infiltration as well as reduced fibrosis and oil cyst formation. Conclusion Postoperative IF improved the retention and outcomes of fat grafting in mice, and could be suggested as a dietary intervention strategy after fat grafting clinically. No Level Assigned This journal requires that authors assign a level of evidence to each submission to which Evidence-Based Medicine rankings are applicable. This excludes Review Articles, Book Reviews, and manuscripts that concern Basic Science, Animal Studies, Cadaver Studies, and Experimental Studies. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266.
- 25 April 2025
- Published by Springer Nature in Aesthetic Plastic Surgery
- p. 1-11
Postoperative Intermittent Fasting Improves Outcome of Autologous Fat Grafting in Mice
Background Autologous fat grafting confronts challenges of inconsistent retention and complications. Intermittent fasting (IF), an emerging dietary management strategy, shows potential in tissue repair and fat metabolism, and yet to know in fat grafting. Objectives The aim of this study is to address the impact of 16:8 IF on the outcome of fat grafting in mice. Methods Male C57BL/6 mice were randomly assigned to postoperative IF regimen group (n = 24) and ad libitum group with unrestricted feeding (n = 24). For postoperative IF group, animals were put on a feeding schedule with 8 hours of unrestricted access to standard diet per day followed by 16-h fasting period after fat grafting. Fat grafts were harvested at 2, 4 and 12 weeks postoperatively. We addressed the mass retention and graft quality through weighting and ultrasound examination. Histological remodeling of fat grafts was evaluated by Masson staining and immunofluorescence staining. Results In comparison with unrestricted feeding, postoperative IF strategies improved the mass retention of fat grafts, and optimized the outcomes characterized by enhanced adipogenesis, accelerated revascularization, facilitated M2 macrophage infiltration as well as reduced fibrosis and oil cyst formation. Conclusion Postoperative IF improved the retention and outcomes of fat grafting in mice, and could be suggested as a dietary intervention strategy after fat grafting clinically. No Level Assigned This journal requires that authors assign a level of evidence to each submission to which Evidence-Based Medicine rankings are applicable. This excludes Review Articles, Book Reviews, and manuscripts that concern Basic Science, Animal Studies, Cadaver Studies, and Experimental Studies. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266.